The Veith Meeting is always such a great event. New York City in the fall can't be beaten. And the quality of the Meeting is exceptional. If you have ever been at the Veith meeting, you know that the format is a rapid fire 5-7 minute presentation format followed by a panel session with questions. And 5 minutes means 5 minutes. I spoke to Dr Veith briefly today and he reinforced that the timliness of the meeting is so important to how it operates. If you ever roll out of bed to make it to the morning session at 6:30 am, Dr Veith is there and if you are there at adjounment at 6:30 pm, Dr Veith is there. He's amazing
On day one, there were conferences focusing on dialysis access, venous disease, cardiovascular disease and wounds. the dialysis access was surprisingly well attended. There seemed to be an overall agreement that the fistula first initiative has pushed us to a point of too many non functioning fistulas (failure to mature) in an attempt to meet the 66% benchmark for fistula creation. This usually leads to an increase in fistulas with a corresponding increase in tunneled catheters.
There is wide enthusiasm for the Flair EndoGraft from Bard Medical. This graft has randomized prospective research showing a significant patency advantage compared to PTA at the interface of graft to vein in AV dialysis.
Other controversies one stage vs two stage BVT
Controversy exists regarding the management of catheter infections. Consensus suggested that it is largely dictated by the organism ie staph epi vs staph aureus. Controversy exists regarding role of cath removal vs cath exchange
Dr Lowel Kabnick presented very compelling information to suggest that the use of Sotradecol in foam sclerotherapy might be considered inappropriate off lable use in some circumstances. However the consensus is that foam sclerotherapy is the preferred method for treatment of spider and reticular veins.
Comments